Steven Lichtman
Stock Analyst at Oppenheimer
(2.84)
# 1,615
Out of 5,143 analysts
72
Total ratings
38.46%
Success rate
11.12%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Steven Lichtman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TNDM Tandem Diabetes Care | Maintains: Outperform | $44 → $22 | $26.90 | -18.22% | 2 | Sep 8, 2025 | |
| PODD Insulet | Maintains: Outperform | $324 → $365 | $245.25 | +48.83% | 8 | Sep 8, 2025 | |
| BSX Boston Scientific | Upgrades: Outperform | $118 → $125 | $75.15 | +66.33% | 4 | Sep 8, 2025 | |
| DXCM DexCom | Maintains: Outperform | $95 → $102 | $73.09 | +39.55% | 9 | Jul 31, 2025 | |
| ZBH Zimmer Biomet Holdings | Maintains: Outperform | $145 → $135 | $99.87 | +35.18% | 7 | Oct 15, 2024 | |
| MNKD MannKind | Maintains: Outperform | $10 → $12 | $5.54 | +116.61% | 2 | Aug 28, 2024 | |
| ALC Alcon | Maintains: Outperform | $103 → $110 | $84.13 | +30.75% | 3 | Aug 22, 2024 | |
| MDT Medtronic | Maintains: Perform | $92 → $94 | $96.75 | -2.84% | 10 | Aug 21, 2024 | |
| RXST RxSight | Maintains: Outperform | $72 → $65 | $8.94 | +627.07% | 8 | Aug 6, 2024 | |
| BWAY BrainsWay | Maintains: Outperform | $10 → $11 | $24.41 | -54.94% | 5 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $12 | $11.43 | +4.99% | 2 | Apr 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $82 → $87 | $82.43 | +5.54% | 1 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $3.5 | $0.47 | +642.78% | 2 | Sep 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $273 → $288 | $381.33 | -24.47% | 2 | Jul 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | $105 | $119.17 | -11.89% | 3 | Jul 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Perform | $150 | $19.75 | +659.49% | 1 | Jul 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $83 → $85 | $83.56 | +1.72% | 3 | Sep 4, 2020 |
Tandem Diabetes Care
Sep 8, 2025
Maintains: Outperform
Price Target: $44 → $22
Current: $26.90
Upside: -18.22%
Insulet
Sep 8, 2025
Maintains: Outperform
Price Target: $324 → $365
Current: $245.25
Upside: +48.83%
Boston Scientific
Sep 8, 2025
Upgrades: Outperform
Price Target: $118 → $125
Current: $75.15
Upside: +66.33%
DexCom
Jul 31, 2025
Maintains: Outperform
Price Target: $95 → $102
Current: $73.09
Upside: +39.55%
Zimmer Biomet Holdings
Oct 15, 2024
Maintains: Outperform
Price Target: $145 → $135
Current: $99.87
Upside: +35.18%
MannKind
Aug 28, 2024
Maintains: Outperform
Price Target: $10 → $12
Current: $5.54
Upside: +116.61%
Alcon
Aug 22, 2024
Maintains: Outperform
Price Target: $103 → $110
Current: $84.13
Upside: +30.75%
Medtronic
Aug 21, 2024
Maintains: Perform
Price Target: $92 → $94
Current: $96.75
Upside: -2.84%
RxSight
Aug 6, 2024
Maintains: Outperform
Price Target: $72 → $65
Current: $8.94
Upside: +627.07%
BrainsWay
May 9, 2024
Maintains: Outperform
Price Target: $10 → $11
Current: $24.41
Upside: -54.94%
Apr 5, 2024
Upgrades: Outperform
Price Target: $12
Current: $11.43
Upside: +4.99%
Feb 29, 2024
Maintains: Outperform
Price Target: $82 → $87
Current: $82.43
Upside: +5.54%
Sep 19, 2023
Reiterates: Outperform
Price Target: $3.5
Current: $0.47
Upside: +642.78%
Jul 28, 2021
Maintains: Perform
Price Target: $273 → $288
Current: $381.33
Upside: -24.47%
Jul 14, 2021
Downgrades: Perform
Price Target: $105
Current: $119.17
Upside: -11.89%
Jul 9, 2021
Initiates: Perform
Price Target: $150
Current: $19.75
Upside: +659.49%
Sep 4, 2020
Maintains: Perform
Price Target: $83 → $85
Current: $83.56
Upside: +1.72%